The combined contraceptive vaginal device (NuvaRing®): A comprehensive review

European Journal of Contraception and Reproductive Health Care

Volumn 10, Issue 2, 2005, Pages 73-78

  Sarkar, N N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Etonorgestrel; Hormonal contraceptive; Inhibition of ovulation; Polymer; Pregnancy; Withdrawal bleeding

Indexed keywords

DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHYLENE VINYL ACETATE COPOLYMER; ETONOGESTREL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; STEROID;

BREAST TENDERNESS; CLINICAL TRIAL; CONTRACEPTIVE DEVICE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG RELEASE; HEADACHE; HORMONAL CONTRACEPTION; HUMAN; INTERMETHOD COMPARISON; LEUKORRHEA; MEDICAL LITERATURE; MEDLINE; MENSTRUAL CYCLE; NAUSEA; ORAL CONTRACEPTION; OVULATION INHIBITION; PREGNANCY; PRIORITY JOURNAL; REVIEW; VAGINA BLEEDING; VAGINA CONTRACEPTION; VAGINA FLORA; VAGINA MUCOSA; VAGINA RING; VAGINITIS; WITHDRAWAL BLEEDING;

ADULT; CONTRACEPTIVE DEVICES, FEMALE; DESOGESTREL; DRUG COMBINATIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; OVULATION; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIALS;

EID: 25444524299     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.1080/13625180500131683     Document Type: Review

References (25)

1. Mishell DRjr, Talas M, Parlow AF, Moyer DL. Contraception by means of a Silastic vaginal ring impregnated with medroxy progesterone acetate. Am J Obstet Gynecol 1970;107:100-7.
2. Sarkar NN. Development of contraceptive vaginal ring for fertility regulation of women. Int Med J 2003;10:119-126.
3. Sarkar NN. Steroidal contraceptive vaginal ring. Int J Clin Pract 2003;57:392-5.
4. Roumen FJ, Dieben TO. Clinical acceptability of an ethylene-vinyl-acetate non-medicated vaginal ring. Contraception 1999;59:59-62.
5. de Leede LGJ, Covers CPM, de Nijs S. A multi-compartment vaginal ring system for independently adjustable release of contraceptive steroids. Contraception 1986;34:589-602.
6. Roumen FJ, Dieben TO, Assendorp R, Bouckaert P. The clinical acceptability of a non-medicated vaginal ring. Contraception 1990;42:201-7.
7. Olsson S-E, Odlind V. Contraception with a vaginal ring releasing 3-keto desogestrel and ethinyloestradiol. Contraception 1990;42:563-72.
8. Timmer CJ, Srivastava N, Dieben TO, Cohen AF. Bioavailability and bioequivalence of etonorgestrel from two oral formulations of desogestrel: Cerazette and Liseta. Eur J Drug Metab Pharmacokinet 1999;24:335-43.
9. Timmer CJ, Mulders TM. Pharmacokinetics of etonorgestrel and ethinyloestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 39:233-42.
10. Bergink EW, Hamburger AD, de Japer E, van der Vies J. Binding of a contraceptive progestogen org-2969 and its metabolites to receptor proteins and human sex hormone binding globulin. J Steroid Biochem 1981;14:175-83.
11. Timmer CJ, Apter D, Voortman G. Pharmacokinetics of 3-keto-desogestrel and ethinyloestradiol released from different types of contraceptive vaginal rings. Contraception 1990;42:629-42.
12. Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring, for ovulation inhibition. Fertil Steril 2001;75:865-70.
13. Mulders TM, Dieben TO, Bennink HJ. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod 2002;17:2594-9.
14. Killick S. Complete and robust ovulation inhibition with NuvaRing. Eur J Contracept Reprod Health Care 2002; 7 (Suppl 2):13-18.
15. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonorgestrel and ethinyloestradiol. Hum Reprod 2001;16:469-75.
16. Roumen FJ. Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing. Eur J Contracept Reprod Health Care 2002; 7 (Suppl 2):19-24.
17. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002;100:585-93.
18. Verhoeven CH, Dieben TO. The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage. Contraception 2004;69:197-9.
19. Haring T, Mulders TM. The combined contraceptive ring NuvaRing and spermicide co-medication. Contraception 2003;67:271-2.
20. Szarewski A. High acceptability and satisfaction with NuvaRing use. Eur J Contacept Reprod Health Care 2002; 7 (Suppl 2):31-6.
21. Novak A, de la Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception 2003;67:187-94.
22. Novak A, de la Loge C, Abetz L. Development and validation of an acceptability and satisfaction questionnaire for a contraceptive vaginal ring, NuvaRing. Pharmacoeconomics 2004;22:245-56.
23. Bjarnadottir RT, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel / ethinyloestradiol. Am J Obstet Gynecol 2002;186:389-95.
24. Vree M. Lower hormone dosage with improved cycle control. Eur J Contracept Reprod Health Care 2002; 7 (Suppl 2):25-30.
25. Roumen FJ, Boon ME, van Velzen D, Dieben TO, Coelingh-Bennink HJ. The cervicovaginal epithelium during 20 cycles' use of a combined contraceptive vaginal ring. Hum Reprod 1996;11:2443-8.